Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): A randomised, open-label phase 3 trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1677-1690

  Place, Andrew E ^a,b   Stevenson, Kristen E ^a   Vrooman, Lynda M ^a,b   Harris, Marian H ^b   Hunt, Sarah K ^a   O'Brien, Jane E ^a   Supko, Jeffrey G ^c   Asselin, Barbara L ^d   Athale, Uma H ^e   Clavell, Luis A ^f   Cole, Peter D ^g   Kelly, Kara M ^h   Laverdiere, Caroline ⁱ   Leclerc, Jean Marie ⁱ   Michon, Bruno ^j   Schorin, Marshall A ^k   Welch, Jennifer J G ^l   Lipshultz, Steven E ^m   Kutok, Jeffery L ⁿ   Blonquist, Traci M ^a   Neuberg, Donna S ^a   Sallan, Stephen E ^a,b   Silverman, Lewis B ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f San Jorge Children s Hospital   (Puerto Rico)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h Department of Medicine   (United States)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^l BROWN UNIVERSITY   (United States)

^m WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Infinity Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; ESCHERICHIA COLI PROTEIN; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVERSE OUTCOME; ARTICLE; AVASCULAR NECROSIS; BACTERIAL INFECTION; BLEEDING; BONE NECROSIS; BRAIN HEMORRHAGE; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DECUBITUS; DEPRESSION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EMBOLISM; EVENT FREE SURVIVAL; FATIGUE; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; INTESTINE PERFORATION; IRON OVERLOAD; LEUKEMIA REMISSION; LIMB PAIN; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MYCOSIS; MYELITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PLEURA DISEASE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEIZURE; SENSORY NEUROPATHY; THROMBOSIS; WOUND; AGE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYMOLOGY; ESCHERICHIA COLI; FEMALE; INFANT; INTENTION TO TREAT ANALYSIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MALE; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CANADA; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84949504525     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00363-0     Document Type: Article

References (25)

1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001, 97:1211-1218.
2. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009, 53:162-167.
3. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011, 152:452-459.
4. Henriksen LT, Harila-Saari A, Ruud E, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer 2015, 62:427-433.
5. Tong WH, Pieters R, de Groot-Kruseman HA, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica 2014, 99:1716-1721.
6. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011, 117:238-249.
7. Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood 2013, 122:507-514.
8. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002, 99:1986-1994.
9. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11:1780-1786.
10. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000, 110:379-384.
11. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharm Ther 2009, 86:651-658.
12. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010, 115:1351-1353.
13. Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol 2014, 32:3874-3882.
14. Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007, 110:1607-1611.
15. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010, 54:199-205.
16. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 2002, 94:2090-2106.
17. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981, 41:4554-4558.
18. Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014, 123:2026-2033.
19. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013, 31:1202-1210.
20. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010, 24:320-334.
21. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
22. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129:734-745.
23. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
24. Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood 2015, 126:69-75.
25. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014, 371:1005-1015.